Jefferies Financial Group Inc. Has $9.92 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Jefferies Financial Group Inc. lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 147.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,476 shares of the medical research company’s stock after buying an additional 30,108 shares during the quarter. Jefferies Financial Group Inc.’s holdings in IQVIA were worth $9,919,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board raised its stake in IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock valued at $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Geode Capital Management LLC raised its stake in IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after purchasing an additional 77,981 shares during the last quarter. Invesco Ltd. raised its stake in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock valued at $481,380,000 after purchasing an additional 59,426 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 2.9%

Shares of NYSE:IQV opened at $148.90 on Monday. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company’s 50-day moving average price is $163.91 and its two-hundred day moving average price is $188.09. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $25.76 billion, a P/E ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the prior year, the firm earned $2.54 EPS. The company’s revenue was up 2.5% on a year-over-year basis. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Mizuho lowered their price target on shares of IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. HSBC lowered shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. UBS Group lowered their price target on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Morgan Stanley boosted their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $231.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.